Familial male-limited precocious puberty: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Alter: pages. Add: pmc, pmid. Removed proxy/dead URL that duplicated identifier. Formatted dashes. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | Category:Intersex variations | #UCB_Category 23/76 |
|||
| Line 27: | Line 27: | ||
The spinal length in boys may be short due to a rapid advance in epiphyseal maturation. It is an [[autosomal dominant]]<ref name=omim/> condition with a [[mutation]] of the [[luteinizing hormone receptor|luteinizing hormone (LH) receptor]]. As FMPP is a gonadotropin-independent form of precocious puberty, [[gonadotropin-releasing hormone agonist]]s (GnRH agonists) are ineffective. Treatment is with drugs that suppress or block the effects of gonadal [[steroidogenesis]], such as [[cyproterone acetate]], [[ketoconazole]], [[spironolactone]], and [[testolactone]].<ref>{{cite journal |vauthors=Reiter EO, Norjavaara E | title=Testotoxicosis: current viewpoint | journal=Pediatr Endocrinol Rev | year=2005 | pages=77–86 | volume=3 | issue=2 | pmid=16361981}}</ref> Alternatively, the combination of the [[androgen receptor]] [[receptor antagonist|antagonist]] [[bicalutamide]] and the [[aromatase inhibitor]] [[anastrozole]] may be used.<ref name="KreherPescovitz2006">{{cite journal | vauthors = Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z | title = Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole | journal = The Journal of Pediatrics | volume = 149 | issue = 3 | pages = 416–20 | date = Sep 2006 | pmid = 16939760 | doi = 10.1016/j.jpeds.2006.04.027 }}</ref> |
The spinal length in boys may be short due to a rapid advance in epiphyseal maturation. It is an [[autosomal dominant]]<ref name=omim/> condition with a [[mutation]] of the [[luteinizing hormone receptor|luteinizing hormone (LH) receptor]]. As FMPP is a gonadotropin-independent form of precocious puberty, [[gonadotropin-releasing hormone agonist]]s (GnRH agonists) are ineffective. Treatment is with drugs that suppress or block the effects of gonadal [[steroidogenesis]], such as [[cyproterone acetate]], [[ketoconazole]], [[spironolactone]], and [[testolactone]].<ref>{{cite journal |vauthors=Reiter EO, Norjavaara E | title=Testotoxicosis: current viewpoint | journal=Pediatr Endocrinol Rev | year=2005 | pages=77–86 | volume=3 | issue=2 | pmid=16361981}}</ref> Alternatively, the combination of the [[androgen receptor]] [[receptor antagonist|antagonist]] [[bicalutamide]] and the [[aromatase inhibitor]] [[anastrozole]] may be used.<ref name="KreherPescovitz2006">{{cite journal | vauthors = Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z | title = Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole | journal = The Journal of Pediatrics | volume = 149 | issue = 3 | pages = 416–20 | date = Sep 2006 | pmid = 16939760 | doi = 10.1016/j.jpeds.2006.04.027 }}</ref> |
||
[[Robert King Stone]], personal physician to American president [[Abraham Lincoln]], described the first case of FMPP in 1852.<ref>{{Cite journal |last=Tao |first=Ya-Xiong |date=November 2008 |title=Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics |
[[Robert King Stone]], personal physician to American president [[Abraham Lincoln]], described the first case of FMPP in 1852.<ref>{{Cite journal |last=Tao |first=Ya-Xiong |date=November 2008 |title=Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics |journal=[[Pharmacology & Therapeutics]] |language=en |publisher=[[Elsevier]] |volume=120 |issue=2 |pages=129–148 |doi=10.1016/j.pharmthera.2008.07.005|pmid=18768149 |pmc=2668812 }}</ref> |
||
==See also== |
==See also== |
||
Revision as of 00:22, 28 June 2022
| Familial male-limited precocious puberty | |
|---|---|
| Other names | Familial sexual precocity |
 | |
| Male-limited precocious puberty has an autosomal dominant pattern of inheritance. However, only males are affected; females with the mutant gene are not affected. | |
Familial male-limited precocious puberty, often abbreviated as FMPP, also known as familial sexual precocity or gonadotropin-independent testotoxicosis,[1] is a form of gonadotropin-independent precocious puberty in which boys experience early onset and progression of puberty.[2] Signs of puberty can develop as early as an age of 1 year.[citation needed]
The spinal length in boys may be short due to a rapid advance in epiphyseal maturation. It is an autosomal dominant[1] condition with a mutation of the luteinizing hormone (LH) receptor. As FMPP is a gonadotropin-independent form of precocious puberty, gonadotropin-releasing hormone agonists (GnRH agonists) are ineffective. Treatment is with drugs that suppress or block the effects of gonadal steroidogenesis, such as cyproterone acetate, ketoconazole, spironolactone, and testolactone.[3] Alternatively, the combination of the androgen receptor antagonist bicalutamide and the aromatase inhibitor anastrozole may be used.[4]
Robert King Stone, personal physician to American president Abraham Lincoln, described the first case of FMPP in 1852.[5]
See also
- Follicle-stimulating hormone insensitivity
- Gonadotropin-releasing hormone insensitivity
- Hypergonadism, hyperandrogenism, and precocious puberty
- Inborn errors of steroid metabolism
- Leydig cell hypoplasia (or LH insensitivity)
References
- ^ a b Online Mendelian Inheritance in Man (OMIM): 176410
- ^ Traggiai C, Stanhope R (2003). "Disorders of pubertal development". Best Pract Res Clin Obstet Gynaecol. 17 (1): 41–56. doi:10.1053/ybeog.2003.0360. PMID 12758225.
- ^ Reiter EO, Norjavaara E (2005). "Testotoxicosis: current viewpoint". Pediatr Endocrinol Rev. 3 (2): 77–86. PMID 16361981.
- ^ Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z (Sep 2006). "Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole". The Journal of Pediatrics. 149 (3): 416–20. doi:10.1016/j.jpeds.2006.04.027. PMID 16939760.
- ^ Tao, Ya-Xiong (November 2008). "Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics". Pharmacology & Therapeutics. 120 (2). Elsevier: 129–148. doi:10.1016/j.pharmthera.2008.07.005. PMC 2668812. PMID 18768149.
External links
- Testotoxicosis at NIH's Office of Rare Diseases
 | This genetic disorder article is a stub. You can help Wikipedia by expanding it. |